Alexander Elias is a London based Partner in Centerview’s life science practices. Having joined Centerview Partners fifteen years ago, Alexander has extensive experience advising companies in the biopharma as well as across the broader life science and healthcare universe.

Alexander recently advised Araris on it’s $400m sale to Taiho / Otsuka, Teva on its $1.5 billion partnership with Sanofi for it’s anti- TL1A candidate duvakitug, and Nxera’s $0.5 billion acquisition of Idorsia’s Japan commercial stage portfolio. Alexander has also advised on industry leading transactions including advising Walgreens Alliance Boots on it’s $23.7 billion take-private by Sycamore Partners, AstraZeneca on its $39 billion acquisition of Alexion, the $8 billion take private of Mediclinic PLC by a consortium of Remgro and MSC, and Galenica on its $2 billion separation through IPO of Galenica Santé to form Vifor Pharma.

Previously Alexander has also advised on numerous life science transactions including Neuroderm’s $1.1 billion sale to Mitsubishi Tanabe, Indvior’s acquisition of Opiant as well as advising CSL on several transactions including their acquisition of Novartis’ influenza vaccine business.

Alexander was formerly a healthcare private equity investor at Permira.

Alexander holds an M.A. in Philosophy, Politics and Economics from the University of Oxford.